Hormone Receptor Status & BRCA: Does Subtype Matter for PARP Use?

Do BRCA1 and BRCA2 mutations behave differently across subtypes? Drs. Iyengar and Robson break down the relationship between hormone receptor status and BRCA mutations — and why both HR+ and triple-negative patients can benefit from PARP inhibition.